Literature DB >> 1544235

IL-2 infusion abrogates humoral immune responses in humans.

D J Gottlieb1, H G Prentice, H E Heslop, C Bello, M K Brenner.   

Abstract

Although IL-2 infusion enhances cell-mediated cytotoxicity in patients with neoplastic disease, administration is paradoxically associated with a modest fall in total serum IgG and an increased risk of infection. We now show that the adverse effects of IL-2 infusion on the humoral immune system are substantial. Although IL-2 induces the B cell growth and differentiating factors IL-4 and IL-6, infusion abrogates primary antibody responses entirely and reduces secondary antibody responses 50-fold following antigen challenge. There is no evidence of the generation of cells with suppressive activity on B cells but IL-2 increases the ratio of circulating virgin:memory cells. These results may help to explain the increased rate of bacterial infection in patients receiving IL-2. As IL-2 plays a central role in the generation of an immune response, the finding that it is also sufficiently immunosuppressive to inhibit primary- and secondary-type antibody responses suggests that exploration of the underlying mechanisms may provide insights into immune system homeostasis and may offer new approaches to therapeutic immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1544235      PMCID: PMC1554326          DOI: 10.1111/j.1365-2249.1992.tb03025.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  B cell growth factor activity of interferon-gamma. Recombinant human interferon-gamma promotes proliferation of anti-mu-activated human B lymphocytes.

Authors:  S Romagnani; M G Giudizi; R Biagiotti; F Almerigogna; C Mingari; E Maggi; C M Liang; L Moretta
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

2.  Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow.

Authors:  J Z Wimperis; M K Brenner; H G Prentice; J E Reittie; P Karayiannis; P D Griffiths; A V Hoffbrand
Journal:  Lancet       Date:  1986-02-15       Impact factor: 79.321

3.  Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1.

Authors:  D F Jelinek; P E Lipsky
Journal:  J Immunol       Date:  1987-11-01       Impact factor: 5.422

4.  T cell help in human antigen-specific antibody responses can be replaced by interleukin 2.

Authors:  R E Callard; S H Smith; J G Shields; R J Levinsky
Journal:  Eur J Immunol       Date:  1986-09       Impact factor: 5.532

5.  Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens.

Authors:  E A Wiebke; S A Rosenberg; M T Lotze
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

6.  Interleukin 2 induces antigen-reactive T cell lines to secrete BCGF-I.

Authors:  M Howard; L Matis; T R Malek; E Shevach; W Kell; D Cohen; K Nakanishi; W E Paul
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

7.  Production of hybridoma growth factor by human monocytes.

Authors:  L A Aarden; E R De Groot; O L Schaap; P M Lansdorp
Journal:  Eur J Immunol       Date:  1987-10       Impact factor: 5.532

8.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

9.  A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease.

Authors:  D J Gottlieb; M K Brenner; H E Heslop; A C Bianchi; C Bello-Fernandez; A B Mehta; A C Newland; A R Galazka; E M Scott; A V Hoffbrand
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

10.  Expression of interleukin 2 receptors on activated human B cells.

Authors:  T A Waldmann; C K Goldman; R J Robb; J M Depper; W J Leonard; S O Sharrow; K F Bongiovanni; S J Korsmeyer; W C Greene
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  4 in total

1.  Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy.

Authors:  C Soubrane; R Mouawad; M Ichen; J Suissa; C Borel; E Vuillemin; A Benhammouda; J P Bizzari; M Weil; D Khayat
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

2.  Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.

Authors:  Alana A Kennedy-Nasser; Stephanie Ku; Paul Castillo-Caro; Yasmin Hazrat; Meng-Fen Wu; Hao Liu; Jos Melenhorst; A John Barrett; Sawa Ito; Aaron Foster; Barbara Savoldo; Eric Yvon; George Carrum; Carlos A Ramos; Robert A Krance; Kathryn Leung; Helen E Heslop; Malcolm K Brenner; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2014-02-26       Impact factor: 12.531

Review 3.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

4.  Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.

Authors:  L T Vlasveld; A Hekman; F A Vyth-Dreese; C J Melief; J J Sein; A C Voordouw; T A Dellemijn; E M Rankin
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.